Statistik Asas
| CIK | 1689375 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Entrada Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Entrada Therapeutics Reports Second Quarter 2025 Financial Results - First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 - - Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 - - Multiple clinical trial sites in U. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 6, 2025 |
Third Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 ENTRADA THERAPEUTICS, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Third Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Entrada Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who a |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commissi |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| June 3, 2025 |
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D. to its Board of Directors Entrada Therapeutics Appoints Maha Radhakrishnan, M.D. to its Board of Directors BOSTON, June 3, 2025 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2025 |
Entrada Therapeutics Reports First Quarter 2025 Financial Results – Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 8, 2025 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. |
|
| April 29, 2025 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| April 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entrada Therapeutics, Inc. |
|
| March 25, 2025 |
Entrada Therapeutics, Inc. 2025 Inducement Equity Plan and forms of award agreements thereunder. Exhibit 99.1 ENTRADA THERAPEUTICS, INC. 2025 INDUCEMENT EQUITY PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Entrada Therapeutics, Inc. 2025 Inducement Equity Plan (the “Plan”). The purpose of the Plan is to enable Entrada Therapeutics, Inc. (the “Company”) to grant equity awards to induce highly qualified prospective employees who are not currently employed |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commissi |
|
| March 24, 2025 |
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping – Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| February 27, 2025 |
2021 Stock Option and Incentive Plan and form of award agreements thereunder Exhibit 10.2 ENTRADA THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Entrada Therapeutics, Inc. (the “Company”) and |
|
| February 27, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Entrada Securities Corporation Massachusetts |
|
| February 27, 2025 |
Entrada Therapeutics, Inc. Second Amended and Restated Insider Trading Policy. Exhibit 19.1 ENTRADA THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the policy of Entrada Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Second Amended and Restated Insider Trading Policy (the “Insid |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entrada Therapeutics, Inc. |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commi |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results – Received FDA authorization to initiate ELEVATE-44-102 in the U. |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commi |
|
| February 24, 2025 |
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 – Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, February 24, 2025 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. |
|
| February 14, 2025 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13G and any future amendments thereto reporting each of the undersigned’s ownership of securities of the Issuer named herein, and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. |
|
| February 3, 2025 |
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy – Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U. |
|
| February 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| January 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| January 15, 2025 |
2025 J.P. Morgan Healthcare Conference NASDAQ: TRDA Exhibit 99.1 2025 J.P. Morgan Healthcare Conference NASDAQ: TRDA Disclaimer This presentation has been prepared by Entrada Therapeutics, Inc. (the “Company”) and shall not constitute an offer to sell o r a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall there be any sale of securities in any jurisdiction in which such of fer , so |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| November 5, 2024 |
Entrada Therapeutics Reports Third Quarter 2024 Financial Results – Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clinical trials for both ENTR-601-44 and ENTR-601-45 in Q4 2024 – – Vertex announced the |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commiss |
|
| August 13, 2024 |
Entrada Therapeutics Reports Second Quarter 2024 Financial Results – Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent plasma and muscle concentration, and exon skipping – – Planning underway for separate global Phase 2 clinical trials for ENTR-601-44 and ENTR-601-45 with regulatory filings anticipated in Q4 2024 – – Completed $100 million registered direct offering led by a U. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 13, 2024 |
EXHIBIT 10.3 ENTRADA THERAPEUTICS, INC. SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Second Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Entrada Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who |
|
| June 26, 2024 |
TRDA / Entrada Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm2418117d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti |
|
| June 24, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of June 24, 2024, by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Investors wish to purchase, severally |
|
| June 24, 2024 |
Exhibit 99.1 Entrada Therapeutics Announces $100 Million Registered Direct Offering – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – BOSTON, June 24, 2024 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives o |
|
| June 24, 2024 |
Exhibit 99.1 Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy – ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments – – ENTR |
|
| June 24, 2024 |
3,367,003 Shares of Common Stock Pre-funded Warrants to Purchase 3,367,003 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-268099 Prospectus Supplement (To prospectus dated November 7, 2022) 3,367,003 Shares of Common Stock Pre-funded Warrants to Purchase 3,367,003 Shares of Common Stock We are offering 3,367,003 shares of our common stock, par value $0.0001 per share (“common stock”), and, in lieu of common stock to certain purchasers that so c |
|
| June 24, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of June 24, 2024 by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this A |
|
| June 24, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| June 24, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| June 24, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK ENTRADA THERAPEUTICS, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2024 Entrada Therap |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13 , 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| June 13, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENTRADA THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Entrada Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was originall |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 7, 2024 |
Entrada Therapeutics Reports First Quarter 2024 Financial Results – Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment from Vertex for the clinical advancement of its Phase 1/2 clinical trial of VX-670 for DM1 – – Cash runway expected through the second quarter of 2026 with $327 million in cash, cash equivalents and marketable securities as of March 31, 2024 – Boston, May 7, 2024 - Entrada Therapeutics, Inc. |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 19, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| March 13, 2024 |
Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT AGT. NO. This Exclusive License Agreement (the “Agreement”) is made this 14th day of December, 2018 (the “Effective Date”) by and between the Ohio State Innovation Found |
|
| March 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commissi |
|
| March 13, 2024 |
Exhibit 97.1 ENTRADA THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 14, 2023 Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered |
|
| March 13, 2024 |
IDB 17-19 Drydock Limited Partnership Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE IDB 17-19 DRYDOCK LIMITED PARTNERSHIP, a Delaware Limited Partnership Landlord and ENTRADA THERAPEUTICS, INC., a Delaware corporation Tenant for The Innovation and Design Building Premises lo |
|
| March 13, 2024 |
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results – Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for the second half of 2024 – – Regulatory applications expected in the fourth quarter of 2024 for the global Phase 2 clinical development of ENTR-601-44 and ENTR-601-45 in people living with DMD – Boston, March 13, 2024 - Entrada Therapeutics, Inc. |
|
| March 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entrada Therapeutics, Inc. |
|
| March 13, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Entrada Securities Corporation Massachusetts |
|
| March 13, 2024 |
Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUBLICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022 SUBLICENSE AGREEMENT This Sublicense Agreement (this “Agreement”) is entered into as |
|
| March 13, 2024 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022 STRATEGIC COLLABORATION AND LICENSE AGREEMENT This Strategi |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| March 13, 2024 |
As filed with the Securities and Exchange Commission on March 13, 2024 As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. |
|
| February 14, 2024 |
EX-99.1 2 tm245846d4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par value |
|
| February 14, 2024 |
TRDA / Entrada Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Entrada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement |
|
| February 14, 2024 |
TRDA / Entrada Therapeutics, Inc. / ROCHE FINANCE LTD - SC 13G/A Passive Investment SC 13G/A 1 tm245948d1sc13ga.htm SC 13G/A CUSIP No. 29384C108 SCHEDULE 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2023 (Date of E |
|
| January 3, 2024 |
Exhibit 99.1 Entrada Therapeutics Promotes Nathan J. Dowden to President - With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada’s operational growth - Boston, Jan. 3, 2024 - Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of pat |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Empl |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| December 6, 2023 |
VIA EDGAR December 6, 2023 Ms. Mary Mast Ms. Angela Connell Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Entrada Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 6, 2023 Form 10-Q for the Six Months Ended June 30, 2023 Filed August 8, 2023 File No. 001-40969 Dear Ms. Mast and Ms. Connell: O |
|
| November 22, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Empl |
|
| November 22, 2023 |
Exhibit 99.1 Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy – Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold on IND application remains in effect – – Cash runway expected thr |
|
| November 13, 2023 |
VIA EDGAR November 13, 2023 Ms. Mary Mast Ms. Angela Connell Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Entrada Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 6, 2023 Form 10-Q for the Six Months Ended June 30, 2023 Filed August 8, 2023 File No. 001-40969 Dear Ms. Mast and Ms. Connell: |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2023 |
Entrada Therapeutics Reports Third Quarter 2023 Financial Results – Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s Duchenne franchise with the selection of its third clinical candidate, ENTR-601-50, for the potential treatment of people living with Duchenne who are exon 50 skipping amenable – – Cash runway expected through 2025 with $354 million in cash, cash equivalents and marketable securities as of September 30, 2023 – BOSTON, Nov. |
|
| November 1, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| November 1, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT This AMENDMENT NO. 1 TO THE STRATEGIC COLLABORATION AND LICENSE AGREEMENT (this “Amendment”) is entered into as of October 26, 20 |
|
| November 1, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO THE SUBLICENSE AGREEMENT This AMENDMENT NO. 1 TO THE SUBLICENSE AGREEMENT (this “Amendment”) is entered into as of October 26, 2023 (the “Amendment Effective Date”) by and between |
|
| September 29, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Comm |
|
| September 29, 2023 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-268099 PROSPECTUS SUPPLEMENT(To prospectus dated November 7, 2022) $150,000,000 Common Stock We have entered into a sales agreement (the “sales agreement”) with Cowen and Company, LLC (“TD Cowen”), dated September 29, 2023, relating to shares of our common stock, $0.0001 par value per share (“common stock”), offered by this |
|
| September 29, 2023 |
Exhibit 1.1 Execution Version Entrada Therapeutics, Inc. $150,000,000 SHARES OF Common Stock, PAR VALUE $0.0001 SALES AGREEMENT September 29, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. |
|
| September 21, 2023 |
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy – Initiation of Phase 1 clinical trial marks Entrada’s transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, September 21, 2023 - Entrada Therapeutics, Inc. |
|
| September 21, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2023 |
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors Exhibit 99.1 Entrada Therapeutics Appoints Gina Chapman to its Board of Directors BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commissi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 8, 2023 |
Entrada Therapeutics Reports Second Quarter 2023 Financial Results – On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 – – $377 million in cash, cash equivalents and marketable securities as of June 30, 2023 – – Cash runway through 2025 – BOSTON, Aug. |
|
| August 1, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| August 1, 2023 |
Exhibit 99.1 Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy – First participant is expected to be dosed in September 2023 with data anticipated in the second half of 2024 – – Cash runway extended through the end of 2025 – BOSTON, August 1, 2023 (GLOBE NEWSWIRE) - Entrada |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| May 10, 2023 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.18 ENTRADA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Entrada Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not empl |
|
| May 10, 2023 |
Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUBLICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022 SUBLICENSE AGREEMENT This Sublicense Agreement (this “Agreement”) is entered into as |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 10, 2023 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022 STRATEGIC COLLABORATION AND LICENSE AGREEMENT This Strategi |
|
| May 10, 2023 |
Entrada Therapeutics Reports First Quarter 2023 Financial Results - $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 4, 2023 |
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors BOSTON, April 4, 2023 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt “Bernie” Zeiher |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commissio |
|
| March 6, 2023 |
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results - Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 - - Actively working to resolve the clinical hold on its IND application for ENTR-601-44 - - Selected ENTR-601-45, expanding the Company’s commitment to include a potential therapy for people living with Duchenne who are amenable to exon 45 skipping - - Cash runway extended into 2H 2025 following the closing of the collaboration with Vertex - BOSTON, March 6, 2023 - Entrada Therapeutics, Inc. |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. |
|
| March 6, 2023 |
Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUBLICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022 SUBLICENSE AGREEMENT This Sublicense Agreement (this “Agreement”) is entered into as |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commissio |
|
| March 6, 2023 |
List of Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Entrada Securities Corporation Massachusetts |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| March 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entrada Therapeutics, Inc. |
|
| March 6, 2023 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND ENTRADA THERAPEUTICS, INC. December 7, 2022 STRATEGIC COLLABORATION AND LICENSE AGREEMENT This Strategi |
|
| February 14, 2023 |
EX-99.1 2 tm236041d13ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par valu |
|
| February 14, 2023 |
TRDA / Entrada Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ENTRADA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| February 9, 2023 |
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) - Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 - - Company’s cash runway extended into the second half of 2025 - BOSTON, February 9, 2023 - Entrada Therapeutics, Inc. |
|
| February 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| February 6, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29384C108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commiss |
|
| January 9, 2023 |
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable ENTR-601-45 Expands Entrada’s Commitment to the Duchenne Community by Advancing a Potential Treatment for People Living with Duchenne Who are Exon 45 Skipping Amenable BOSTON, Monday, January 9 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. |
|
| December 19, 2022 |
Exhibit 99.1 Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy BOSTON, Monday, December 19, 2022 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV?)-therapeutics as a new class of medicines, today |
|
| December 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Empl |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S Employ |
|
| December 8, 2022 |
? Exhibit 10.1 ? Execution Version ? STOCK PURCHASE AGREEMENT ? By and Between ? ENTRADA THERAPEUTICS,?INC. ? AND ? VERTEX PHARMACEUTICALS INCORPORATED ? Dated as of December?7, 2022 ? ? ? ? ? TABLE OF CONTENTS ? ? ? ? Page ? ? ? ? 1. Definitions 1 ? ? ? ? ? 1.1 Defined Terms 1 ? 1.2 Additional Defined Terms 3 ? ? ? ? 2. Purchase and Sale of Common Stock 4 ? ? ? ? 3. Closing Date; Deliveries 4 ? ? |
|
| December 8, 2022 |
Exhibit 99.1 Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) - Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada?s EEV-investigational candidate for |
|
| November 7, 2022 |
Entrada Therapeutics Reports Third Quarter 2022 Financial Results On track to submit Investigational New Drug application to the U. |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 4, 2022 |
VIA EDGAR November 4, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 1, 2022 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.6 ENTRADA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s |
|
| November 1, 2022 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.5 ENTRADA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| November 1, 2022 |
EX-FILING FEES 6 tm2229338d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Entrada Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit |
|
| November 1, 2022 |
As filed with the Securities and Exchange Commission on November 1, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 1, 2022 Registration No. |
|
| August 11, 2022 |
Entrada Therapeutics Reports Second Quarter 2022 Financial Results On track to submit Investigational New Drug application to the U. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction of incorporation) (Commiss |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 3, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (IRS Employer of |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (IRS Employer of |
|
| May 12, 2022 |
Exhibit 99.1 Entrada Therapeutics Reports First Quarter 2022 Financial Results Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 $263.9 million in cash, cash equivalents and marketable |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 19, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???????? ??) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission O |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 22, 2022 |
Exhibit 10.1 LEASE IDB 17-19 DRYDOCK LIMITED PARTNERSHIP, a Delaware Limited Partnership Landlord and ENTRADA THERAPEUTICS, INC., a Delaware corporation Tenant for The Innovation and Design Building Premises located on the Fifth (5th) and Sixth (6th) Floors of One Design Center Place Boston, Massachusetts March 16, 2022 TABLE OF CONTENTS Article I. BASIC LEASE INFORMATION 1 Article II. 2 Section 2 |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 81-3983399 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 84-3983399 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| March 15, 2022 |
List of Subsidiaries of the Registrant. ? Exhibit 21.1 SUBSIDIARIES ? ? ? Subsidiary Jurisdiction of Incorporation Entrada Securities Corporation Massachusetts ? ? |
|
| March 15, 2022 |
Exhibit 99.1 Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of EEV- therapeutic candidates BOSTON, Mass., March 15, 2022 ? Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmac |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entrada Therapeutics, Inc. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock of Entrada Therapeutics, Inc., a Delaware corporation (the ?Company,? ?we,? ?us,? and ?our?), is a summary of certain provisions of our securities that are registered under Section 12 of the Securities and Exc |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, par value $0.0001 per share, of Entrada Therapeutics, |
|
| February 14, 2022 |
TRDA / Entrada Therapeutics Inc / Redmile Group, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Entrada Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2022 |
TRDA / Entrada Therapeutics Inc / ROCHE FINANCE LTD - SC 13G Passive Investment CUSIP No. 29384C108 SCHEDULE 13G Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stateme |
|
| February 8, 2022 |
TRDA / Entrada Therapeutics Inc / MRL Ventures Fund LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 8, 2022 |
Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the ?Act?) by and among the parties listed below, each referenced to herein as a ?Joint Filer.? The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereu |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29384C108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| December 16, 2021 |
TRDA / Entrada Therapeutics Inc / BAKER BROS. ADVISORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| December 16, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D (and any amendments thereto) need be filed with respect to the beneficial ownership by each of the undersigned of securities of Entrada Therapeutics, Inc. This Agreement may b |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 9, 2021 |
EX-99.1 2 tm2134805d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entrada Therapeutics Reports Third Quarter 2021 Financial Results Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Mass., December 9, 2021 – Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (E |
|
| December 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 84-3983399 (State or other jurisdiction (Commission (I.R.S. Emplo |
|
| November 12, 2021 |
TRDA / Entrada Therapeutics Inc / MPM BioVentures 2014, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Entrada Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29384C 108 (CUSIP Number) Luke Evnin MPM Asset Management 450 Kendall Street Cambridge, MA 01242 Telephone: (617) 425-9200 (Name, Address and Telephone Number of Perso |
|
| November 12, 2021 |
TRDA / Entrada Therapeutics Inc / 5AM Ventures V, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Entrada Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 29384C 108 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 993-8565 (Name, Address and |
|
| November 12, 2021 |
EX-99.C 2 d255955dex99c.htm EX-99.C Exhibit C Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Entrada Therapeutics, Inc. is filed on behalf of each of the undersigned. Date: November 11, 2021 MPM BIOVENTURES 2014, L.P. By: MPM BioVen |
|
| November 10, 2021 |
TRDA / Entrada Therapeutics Inc / BAKER BROS. ADVISORS LP - SCHEDULE 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 2, 2021 |
Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENTRADA THERAPEUTICS, INC. Entrada Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Entrada Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secretar |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40969 84-3983399 (State or other jurisdiction of incorporation) (Commis |
|
| November 2, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ENTRADA THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors of the Corporation (the ?Board |
|
| November 1, 2021 |
Prospectus 9,075,000 Shares Common Stock TABLE OF CONTENTS ?Filed Pursuant to 424(b)(4) ?Registration Nos. 333-260160 and 333-260572? Prospectus 9,075,000 Shares Common Stock ? This is an initial public offering of shares of common stock of Entrada Therapeutics, Inc. All of the 9,075,000 shares of common stock are being sold by us. Prior to this offering, there has been no public market for our common stock. The initial public offering p |
|
| October 28, 2021 |
As filed with the Securities and Exchange Commission on October 28, 2021 As filed with the Securities and Exchange Commission on October 28, 2021 Registration No. |
|
| October 28, 2021 |
As filed with the Securities and Exchange Commission on October 28, 2021 As filed with the Securities and Exchange Commission on October 28, 2021 Registration No. |
|
| October 26, 2021 |
Form 8-A (File No. 001-40969) as filed with the SEC on October 26, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Entrada Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-3983399 (State of incorporation or organization) (I.R.S. Employer Identification No.) 6 Tide Street Bos |
|
| October 26, 2021 |
VIA EDGAR October 26, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 26, 2021 |
October 26, 2021 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Margaret Schwartz and Celeste Murphy Re: Entrada Therapeutics, Inc. (the ?Company?) Registration Statement on Form S-1 File No. 333-260160 Ladies and Gentleman: In connection with the above-referenced Registration Statement, we wish |
|
| October 25, 2021 |
Exhibit 10.2 ENTRADA THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Entrada Therapeutics, Inc. (the ?Company?) and |
|
| October 25, 2021 |
EX-4.1 4 tm2123090d10ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Entrada Therapeutics, Inc (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, up |
|
| October 25, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 25, 2021. |
|
| October 25, 2021 |
Exhibit 10.8 ENTRADA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Entrada Therapeutics, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its sub |
|
| October 25, 2021 |
Exhibit 10.12 AMENDED AND RESTATED STRATEGIC ADVISORY AGREEMENT THIS AMENDED AND RESTATED STRATEGIC ADVISORY AGREEMENT (together with the attached Business Terms Exhibit, the ?Agreement?) by and between Entrada Therapeutics, Inc., a Delaware corporation with a principal business address 6 Tide Street, Boston, MA 02210 (?Entrada?), and Peter Kim (?Strategic Advisor?). This Agreement shall become ef |
|
| October 25, 2021 |
Exhibit 10.6 ENTRADA THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Entrada Therapeutics, Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their goals and in |
|
| October 25, 2021 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) dated as of [DATE] is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the ?Company?), and [INSERT] (the ?Executive?). This Agreement shall become effective as of [DATE], which, unless otherwise provided by the Company, will be the first day of the Executive?s employment with the Company (the ?Start Da |
|
| October 25, 2021 |
EX-10.5 9 tm2123090d10ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 ENTRADA THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified indi |
|
| October 25, 2021 |
Exhibit 10.9 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) dated as of October 20, 2021 is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the ?Company?), and Dipal Doshi (the ?Executive?). This Agreement shall become effective as of the closing of the Company?s first underwritten public offering (the ?IPO?) of its eq |
|
| October 25, 2021 |
Exhibit 3.2 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENTRADA THERAPEUTICS, INC. Entrada Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1.????????????The name of the Corporation is Entrada Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with t |
|
| October 25, 2021 |
EX-3.4 3 tm2123090d10ex3-4.htm EXHIBIT 3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ENTRADA THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by |
|
| October 25, 2021 |
EX-10.4 8 tm2123090d10ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 ENTRADA THERAPEUTICS, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified in |
|
| October 25, 2021 |
Exhibit 10.3 ENTRADA THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Entrada Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Entrada Therapeutics, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.0001 per share |
|
| October 25, 2021 |
Exhibit 10.11 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) dated as of October 20, 2021 is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the ?Company?), and Nathan Dowden (the ?Executive?). This Agreement shall become effective as of the closing of the Company?s first underwritten public offering (the ?IPO?) of its |
|
| October 25, 2021 |
EX-10.10 14 tm2123090d10ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (“Agreement”) dated as of October 20, 2021 is made by and between Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), and Natarajan Sethuraman (the “Executive”). This Agreement shall become effective as of the closing of the Compan |
|
| October 8, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 Entrada Therapeutics, Inc. Common Stock Underwriting Agreement [●], 2021 Goldman Sachs & Co. LLC Cowen and Company, LLC Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York, New |
|
| October 8, 2021 |
EX-10.14 8 tm2123090d7ex10-14.htm EXHIBIT 10.14 Exhibit 10.14 License Agreement This License Agreement, made and entered into as of February 28, 2020 (“Agreement”), is by and between Entrada Therapeutics, Inc., a Delaware domestic corporation, having a place of business located at 50 Northern Avenue, Boston MA 02210 (“Licensee”) and MIL 6T, LLC a Delaware limited liability company having a place o |
|
| October 8, 2021 |
Goodwin Procter llp 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 October 8, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz, Celeste Murphy, Al Pavot and Jeanne Bennett Re: Entrada Therapeutics, Inc. Amendment No. 1 to Draft Registrat |
|
| October 8, 2021 |
EX-10.1 6 tm2123090d7ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CYCLOPORTERS 2016 Stock Incentive Plan 1. Purpose. The purpose of this plan (the “Plan”) is to secure for CycloPorters, Inc., a Delaware corporation (the “Company”) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and su |
|
| October 8, 2021 |
Bylaws of Registrant, as currently in effect. Exhibit 3.3 BY-LAWS OF CYCLOPORTERS, INC. (the “Corporation”) Section 1. CERTIFICATE OF INCORPORATION AND BY-LAWS 1.1 These by-laws are subject to the certificate of incorporation of the corporation. In these by-laws, references to the certificate of incorporation and by-laws mean the provisions of the certificate of incorporation and the by-laws as are from time to time in effect. Section 2. OFFI |
|
| October 8, 2021 |
EX-10.13 7 tm2123090d7ex10-13.htm EXHIBIT 10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT AGT. NO. This Exclusive License Agreement (the “Agreement”) is made this 14th day of December, 2018 (the “Effective Date” |
|
| October 8, 2021 |
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of this 29th day of March, 2021, by and among Entrada Therapeutics, Inc. (f/k/a CycloPorters, Inc.), a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreemen |
|
| October 8, 2021 |
Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENTRADA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Entrada Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That the name of this corpo |
|
| October 8, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 8, 2021. |
|
| September 15, 2021 |
Goodwin Procter llp 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 September 15, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz, Celeste Murphy, Al Pavot and Jeanne Bennett Re: Entrada Therapeutics, Inc. Draft Registration Statement on |
|
| September 15, 2021 |
EXCLUSIVE LICENSE AGREEMENT AGT. NO.________ EX-10.12 2 filename2.htm Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT AGT. NO. This Exclusive License Agreement (the “Agreement”) is made this 14th day of December, 2018 (the “Effective Date”) by and between the Oh |
|
| September 15, 2021 |
TABLE OF CONTENTS FOIA Confidential Treatment Requested? As confidentially submitted to the Securities and Exchange Commission on September 15, 2021 as Amendment No. |
|
| August 6, 2021 |
DRS 1 filename1.htm TABLE OF CONTENTS FOIA Confidential Treatment Requested As confidentially submitted to the Securities and Exchange Commission on August 6, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was |
|
| August 6, 2021 |
EX-3.1 2 filename2.htm Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENTRADA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Entrada Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That |
|
| August 6, 2021 |
CYCLOPORTERS 2016 Stock Incentive Plan Exhibit 10.1 CYCLOPORTERS 2016 Stock Incentive Plan 1. Purpose. The purpose of this plan (the ?Plan?) is to secure for CycloPorters, Inc., a Delaware corporation (the ?Company?) and its shareholders the benefits arising from capital stock ownership by employees, officers and directors of, and consultants or advisors to, the Company and its parent and subsidiary corporations who are expected to con |
|
| August 6, 2021 |
EX-10.13 6 filename6.htm Exhibit 10.13 License Agreement This License Agreement, made and entered into as of February 28, 2020 (“Agreement”), is by and between Entrada Therapeutics, Inc., a Delaware domestic corporation, having a place of business located at 50 Northern Avenue, Boston MA 02210 (“Licensee”) and MIL 6T, LLC a Delaware limited liability company having a place of business located at 6 |
|
| August 6, 2021 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.2 4 filename4.htm Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of this 29th day of March, 2021, by and among Entrada Therapeutics, Inc. (f/k/a CycloPorters, Inc.), a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is refer |
|
| August 6, 2021 |
BY-LAWS CYCLOPORTERS, INC. (the “Corporation”) EX-3.3 3 filename3.htm Exhibit 3.3 BY-LAWS OF CYCLOPORTERS, INC. (the “Corporation”) Section 1. CERTIFICATE OF INCORPORATION AND BY-LAWS 1.1 These by-laws are subject to the certificate of incorporation of the corporation. In these by-laws, references to the certificate of incorporation and by-laws mean the provisions of the certificate of incorporation and the by-laws as are from time to time in |
